TG Therapeutics
TGTX
97 hedge funds and large institutions have $359M invested in TG Therapeutics in 2017 Q1 according to their latest regulatory filings, with 30 funds opening new positions, 37 increasing their positions, 18 reducing their positions, and 18 closing their positions.
256% more capital invested
Capital invested by funds: $101M → $359M (+$258M)
106% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 18
74% more call options, than puts
Call options by funds: $8.13M | Put options by funds: $4.67M
67% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 18
14.47% more ownership
Funds ownership: 39.64% → 54.11% (+14%)
7% more funds holding
Funds holding: 91 → 97 (+6)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$19.1M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$19.1M |
| 3 |
Franklin Resources
San Mateo,
California
|
+$13.9M |
| 4 |
Jennison Associates
New York
|
+$9.88M |
| 5 |
SAM
Senzar Asset Management
New York
|
+$8.18M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$2.5M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$2.18M |
| 3 |
BM
Bridger Management
New York
|
-$2.14M |
| 4 |
EU
Emory University
Atlanta,
Georgia
|
-$1.76M |
| 5 |
GC
Guggenheim Capital
Chicago,
Illinois
|
-$1.12M |
TGTX Hedge Fund Activity: Q1 2017 in Review
97 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in TG Therapeutics (TGTX) for Q1 2017, worth a combined $359M — up 256% from $101M a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new TGTX positions and 18 closed out — a net gain of 12 holders — while 37 added to existing stakes and 18 trimmed.
The largest buyer was BlackRock, adding an estimated $19.1M. The largest seller was Eventide Asset Management, exiting entirely with an estimated $2.5M sold.
- 97 institutional investors held TG Therapeutics (TGTX) as of Q1 2017, up from 91 in Q4 2016.
- Funds reported $359M of TG Therapeutics stock for Q1 2017, up 256% quarter-over-quarter.
- 30 funds opened new TG Therapeutics positions in Q1 2017 and 18 closed out, a net change of +12 holders.
- The largest TG Therapeutics buyer in Q1 2017 was BlackRock, an estimated $19.1M added.
- The largest TG Therapeutics seller in Q1 2017 was Eventide Asset Management, an estimated $2.5M sold.
Based on aggregated 13F filings for Q1 2017.